Sudhakar Katakam

Array ( [id] => 17082045 [patent_doc_number] => 20210277051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME [patent_app_type] => utility [patent_app_number] => 17/255074 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993415 [patent_doc_number] => 20200172578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 [patent_app_type] => utility [patent_app_number] => 16/624989 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 1057 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102424 [patent_doc_number] => 11542299 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Method for synthesizing peptide containing N-substituted amino acid [patent_app_type] => utility [patent_app_number] => 16/619388 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 21 [patent_no_of_words] => 34868 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16619388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986355 [patent_doc_number] => 20190062335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => IMIDAZOPYRAZINONES AS PDE1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/002116 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13603795 [patent_doc_number] => 20180353446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => COMPOSITIONS AND METHODS OF TREATING AND/OR PREVENTING CANCER [patent_app_type] => utility [patent_app_number] => 16/002441 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16060883 [patent_doc_number] => 10689373 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => 1,2-substituted cyclopentanes as orexin receptor antagonists [patent_app_type] => utility [patent_app_number] => 15/995586 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43372 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 568 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590823 [patent_doc_number] => 20180346960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Fluorogenic peptide substrates for in solution and solid phase factor Xa measurements [patent_app_type] => utility [patent_app_number] => 15/993442 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440633 [patent_doc_number] => 20180271859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY [patent_app_type] => utility [patent_app_number] => 15/990935 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087015 [patent_doc_number] => 20200197494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => PEPTIDE COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/615362 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18171763 [patent_doc_number] => 11571456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Process for the linear synthesis of gram-positive class II bacteriocins and compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 16/616322 [patent_app_country] => US [patent_app_date] => 2018-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 17535 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13492785 [patent_doc_number] => 20180297935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/986059 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 123186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15986059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13493025 [patent_doc_number] => 20180298055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 15/982837 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57048 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649637 [patent_doc_number] => 20200087348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => MODIFIED MICROCYSTINS AND NODULARINS [patent_app_type] => utility [patent_app_number] => 16/605264 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16605264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883790 [patent_doc_number] => 20210169985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => METHODS FOR TREATING GRAM POSITIVE BACTERIAL INFECTION [patent_app_type] => utility [patent_app_number] => 17/052383 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012699 [patent_doc_number] => 20200181192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => DISULFIDE BIOCONJUGATION [patent_app_type] => utility [patent_app_number] => 16/608587 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386281 [patent_doc_number] => 20180244682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/963273 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 311 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15963273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383759 [patent_doc_number] => 20180243421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => IMMUNOSTIMULATING AGENT [patent_app_type] => utility [patent_app_number] => 15/962250 [patent_app_country] => US [patent_app_date] => 2018-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15962250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519421 [patent_doc_number] => 20180311253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 15/962837 [patent_app_country] => US [patent_app_date] => 2018-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15962837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16816803 [patent_doc_number] => 11001609 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Cell permeable cyclic peptide scaffolds [patent_app_type] => utility [patent_app_number] => 16/604482 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31830 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648771 [patent_doc_number] => 10925925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors [patent_app_type] => utility [patent_app_number] => 15/951850 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 18006 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951850 [rel_patent_id] =>[rel_patent_doc_number] =>)